# The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.

> **NCT06600412** · PHASE2 · RECRUITING · sponsor: **River 3 Renal Corp.** · enrollment: 60 (estimated)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** R3R01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06600412
- **Lead sponsor:** River 3 Renal Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600412, "The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06600412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*